Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.49 |
| ▸ | SHBG | P04278 | 1/20 | 0.49 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16010005 | 0.80 | GPBAR1 (0.45) | LMNAGPBAR1SHBGSERPINA6 | |
| SCHEMBL14509336 | 0.79 | LMNA (0.61) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL19253304 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL14046194 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL19733265 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL19750433 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL19253297 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL17693865 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL18575975 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 | |
| SCHEMBL15426612 | 0.77 | LMNA (0.75) | LMNAGPBAR1SHBGSERPINA6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365502-B2 | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256805-A1 | NEUROACTIVE SUBSTITUTED CYCLOPENTA[b]PHENANTHRENES AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRB1, GABRB2 | LMNA 4611/4885GPBAR1 103/4885SHBG 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.